Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Lemaitre Vascular's Depreciation & Amortization (CF) rose 770.82% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 680.85%. This contributed to the annual value of $9.7 million for FY2024, which is 162.9% up from last year.
  • Lemaitre Vascular's Depreciation & Amortization (CF) amounted to $2.6 million in Q3 2025, which was up 770.82% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Lemaitre Vascular's Depreciation & Amortization (CF) registered a high of $2.9 million during Q3 2021, and its lowest value of $2.3 million during Q4 2022.
  • Over the past 5 years, Lemaitre Vascular's median Depreciation & Amortization (CF) value was $2.4 million (recorded in 2023), while the average stood at $2.5 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 7061.12% in 2021, then crashed by 2066.57% in 2022.
  • Quarter analysis of 5 years shows Lemaitre Vascular's Depreciation & Amortization (CF) stood at $2.9 million in 2021, then decreased by 20.67% to $2.3 million in 2022, then grew by 6.77% to $2.4 million in 2023, then increased by 1.43% to $2.5 million in 2024, then increased by 5.45% to $2.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.6 million for Q1 2025.